Helsinn and Riemser Extend Relationship in Germany / License Agreement for Germany on New Therapy in Development for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV)
Lugano, Switzerland and Greifswald, Germany (ots) - Helsinn Healthcare SA, Switzerland and Riemser Arzneimittel AG, German licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announce today the signing of a licensing agreement granting Riemser the commercialization rights for a ...